Does EVOLOCUMAB Cause Prostatic specific antigen increased? 34 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 34 reports of Prostatic specific antigen increased have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.0% of all adverse event reports for EVOLOCUMAB.
34
Reports of Prostatic specific antigen increased with EVOLOCUMAB
0.0%
of all EVOLOCUMAB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Prostatic specific antigen increased From EVOLOCUMAB?
Of the 34 reports, and 1 (2.9%) were considered life-threatening.
Is Prostatic specific antigen increased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 34 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Prostatic specific antigen increased?
ENZALUTAMIDE (3,731)
LEUPROLIDE (2,432)
ABIRATERONE (1,581)
RADIUM RA-223 DICHLORIDE (449)
RELUGOLIX (335)
BICALUTAMIDE (322)
DOCETAXEL (282)
APALUTAMIDE (251)
DENOSUMAB (220)
LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)
Which EVOLOCUMAB Alternatives Have Lower Prostatic specific antigen increased Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE